CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...
Phase 2
Durham, North Carolina, United States and 24 other locations
cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...
Phase 1, Phase 2
Durham, North Carolina, United States and 20 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Durham, North Carolina, United States and 51 other locations
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...
Phase 2
Durham, North Carolina, United States and 55 other locations
antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...
Phase 2, Phase 3
Durham, North Carolina, United States and 65 other locations
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...
Phase 3
Durham, North Carolina, United States and 4 other locations
of up to 2 dose selection cohorts to evaluate the safety and tolerability of dapansutrile + pembrolizumab in patients with PD-1 resistant melanoma...
Phase 1, Phase 2
Durham, North Carolina, United States
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Durham, North Carolina, United States and 183 other locations
be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...
Phase 2
Durham, North Carolina, United States and 32 other locations
of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy....
Phase 2, Phase 3
Durham, North Carolina, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal